[go: up one dir, main page]

WO2008036835A3 - Procédés et compositions permettant la régulation à la hausse de l'activité de la peroxirédoxine - Google Patents

Procédés et compositions permettant la régulation à la hausse de l'activité de la peroxirédoxine Download PDF

Info

Publication number
WO2008036835A3
WO2008036835A3 PCT/US2007/079068 US2007079068W WO2008036835A3 WO 2008036835 A3 WO2008036835 A3 WO 2008036835A3 US 2007079068 W US2007079068 W US 2007079068W WO 2008036835 A3 WO2008036835 A3 WO 2008036835A3
Authority
WO
WIPO (PCT)
Prior art keywords
peroxiredoxin
activity
sample
subjects
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/079068
Other languages
English (en)
Other versions
WO2008036835A2 (fr
Inventor
Ish Khanna
Ram Pillarisetti
Uday Saxena
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reddy US Therapeutics Inc
Original Assignee
Reddy US Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddy US Therapeutics Inc filed Critical Reddy US Therapeutics Inc
Priority to US12/441,924 priority Critical patent/US20100297673A1/en
Publication of WO2008036835A2 publication Critical patent/WO2008036835A2/fr
Anticipated expiration legal-status Critical
Publication of WO2008036835A3 publication Critical patent/WO2008036835A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un nouveau procédé d'identification de composés capables de réguler à la hausse l'activité de la peroxirédoxine. Le procédé inclut les étapes consistant à fournir un échantillon de cellules qui expriment la peroxirédoxine, fournir un échantillon d'un composé candidat, mettre en contact l'échantillon de cellules et l'échantillon de composé, et mesurer un indicateur quantitatif de l'activité de la peroxirédoxine dans l'échantillon de cellules après l'étape de mise en contact. L'invention concerne également les inducteurs de la peroxirédoxine identifiés par le procédé et les utilisations pour donc réguler à la hausse l'activité de la peroxirédoxine chez des sujets et pour abaisser les taux des lipoprotéines à faible densité (LDL) et/ou des lipoprotéines à très faible densité (VLDL) et pour prévenir ou traiter une athérosclérose et des troubles inflammatoires. L'invention concerne aussi un procédé de traitement des maladies inflammatoires et cardio-vasculaires qui comprend l'étape consistant à fournir à un patient nécessitant un traitement une quantité efficace d'une composition qui augmente le taux de protéine de peroxirédoxine ou l'activité de la peroxirédoxine.
PCT/US2007/079068 2006-09-20 2007-09-20 Procédés et compositions permettant la régulation à la hausse de l'activité de la peroxirédoxine Ceased WO2008036835A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/441,924 US20100297673A1 (en) 2006-09-20 2007-09-20 Methods and compositions for upregulation of peroxiredoxin activity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84605706P 2006-09-20 2006-09-20
US60/846,057 2006-09-20
US95180107P 2007-07-25 2007-07-25
US60/951,801 2007-07-25

Publications (2)

Publication Number Publication Date
WO2008036835A2 WO2008036835A2 (fr) 2008-03-27
WO2008036835A3 true WO2008036835A3 (fr) 2009-05-14

Family

ID=39201281

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/079068 Ceased WO2008036835A2 (fr) 2006-09-20 2007-09-20 Procédés et compositions permettant la régulation à la hausse de l'activité de la peroxirédoxine

Country Status (2)

Country Link
US (1) US20100297673A1 (fr)
WO (1) WO2008036835A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006505290A (ja) 2002-11-10 2006-02-16 インスティテュート オブ セル バイオフィジクス ロシアン アカデミー オブ サイエンシーズ 抗酸化医薬化合物、ポリペプチドの産生方法、治療方法
CN102346190A (zh) * 2011-01-24 2012-02-08 中国人民解放军第三军医大学 用于检测生物标本中的过氧化物还原酶ⅳ的双抗夹心elisa试剂盒及其方法与运用
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2015003360A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
JP6529492B2 (ja) 2013-07-11 2019-06-12 アジオス ファーマシューティカルズ， インコーポレイテッド 癌の処置のためのｉｄｈ２突然変異体阻害剤としての２，４−または４，６−ジアミノピリミジン化合物
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
AU2015229214B2 (en) 2014-03-14 2019-07-11 Les Laboratoires Servier Pharmaceutical compositions of therapeutically active compounds
MX390531B (es) 2015-10-15 2025-03-20 Servier Lab Terapia de combinacion para tratar tumores malignos.
MA43000B1 (fr) 2015-10-15 2021-11-30 Celgene Corp Polythérapie pour le traitement de tumeurs malignes
JP6934972B2 (ja) * 2016-03-29 2021-09-15 ポーラ化成工業株式会社 ペルオキシレドキシン発現増大剤のスクリーニング方法
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040191819A1 (en) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corporation Expression profiles for breast cancer and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040191819A1 (en) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corporation Expression profiles for breast cancer and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CESARATTO ET AL.: "Overoxidation of peroxiredoxins as an immediate and sensitive marker of oxidative stress in HepG2 cells and its application to the redox effects induced by ischemia/reperfusion in human liver.", FREE RADICAL RESEARCH., vol. 39, no. 3, March 2005 (2005-03-01), pages 255 - 268, XP009152654, DOI: doi:10.1080/10715760400029603 *
KIM ET AL.: "Role ofPeroxiredoxins in REgulating Intracellular Hydrogen Peroxide and Hydrogen Peroxide-induced Apoptosis in Thyroid Cells.", J. BIOL. CHEM., vol. 275, no. 24, June 2000 (2000-06-01), pages 18266 - 18270 *

Also Published As

Publication number Publication date
WO2008036835A2 (fr) 2008-03-27
US20100297673A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
WO2008036835A3 (fr) Procédés et compositions permettant la régulation à la hausse de l'activité de la peroxirédoxine
Khojah et al. Reactive oxygen and nitrogen species in patients with rheumatoid arthritis as potential biomarkers for disease activity and the role of antioxidants
Tyrrell et al. Lead (Pb) exposure promotes diabetes in obese rodents
WO2012149493A3 (fr) Polythérapie par hsp90
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
WO2009090553A3 (fr) Compositions et procédés de détection de peptides post-arrêts
MX2013004305A (es) Metodos para determinar isotipos de anticuerpos anti-farmacos.
JP2011503547A5 (fr)
WO2013190075A3 (fr) Biomarqueurs spécifiques pour un carcinome hépatocellulaire (hcc)
WO2011149942A3 (fr) Compositions et procédés pour l'analyse de peptides plasmatiques
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
WO2010144150A3 (fr) Procédés et systèmes analytiques en temps réel
WO2013068374A3 (fr) Biomarqueurs lipidomiques pour prédire l'évolution de maladies cardiovasculaires chez des patients atteints de coronaropathie et suivant un traitement par statine
HK1202157A1 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
BR112015017403A2 (pt) biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória
WO2011126833A3 (fr) Facteurs anti-inflammatoires
WO2012050365A3 (fr) Marqueur biologique pour diagnostiquer un glioblastome ou prévoir le pronostic de patients souffrant d'un glioblastome, et son utilisation
MX357429B (es) Predictores para el tratamiento del cáncer.
BR112012007555A2 (pt) biomarcadores para prever a sensibilidade e resposta de doenças mediadas por quinase de proteína ck2 a inibidores de ck2
WO2013026026A3 (fr) Correction de décalage pour analyse spectrale
ATE549638T1 (de) 13c-mr-bildgebung oder spektroskopie von zelltod
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
EA201491411A1 (ru) Растворимый manf при поражениях бета-клеток поджелудочной железы
Roop-Ngam et al. Isolation and characterizations of oxalate-binding proteins in the kidney
WO2008127387A3 (fr) Modulateurs d'holoenzyme de phosphatase 2a de protéine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07842901

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07842901

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12441924

Country of ref document: US